ASSOC. PROF. PETER SHANE HAMBLIN (Orcid ID : 0000-0002-6280-865X)

Article type : Letters to the editor (reply)

Article begins on page three of this document.

Title | Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis

Authors:

<table>
<thead>
<tr>
<th>Title</th>
<th>First name</th>
<th>Mid initial</th>
<th>Last name</th>
<th>Postnom (eg, PhD)</th>
<th>Position1</th>
<th>Address1</th>
<th>Position2</th>
<th>Address2</th>
<th>Tel</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Assoc. Prof.</td>
<td>Peter</td>
<td>S</td>
<td>Hamblin</td>
<td>MB BS(Hons), FRACP</td>
<td>1</td>
<td>2</td>
<td>038345 6666</td>
<td><a href="mailto:peter.hamblin@wh.org.au">peter.hamblin@wh.org.au</a></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Dr.</td>
<td>Rosemary</td>
<td>Wong</td>
<td>MBBS(Melb) MD (Melb), FRACP</td>
<td>Endocrinologist</td>
<td>3</td>
<td></td>
<td></td>
<td><a href="mailto:wong.rose.m@gmail.com">wong.rose.m@gmail.com</a></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Prof.</td>
<td>Leon</td>
<td>A</td>
<td>Bach</td>
<td></td>
<td>4</td>
<td>5</td>
<td></td>
<td><a href="mailto:L.Bach@alfred.org.au">L.Bach@alfred.org.au</a></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Number of corresponding author: 1

Number of alternative corresponding author: 0

Addresses:

<table>
<thead>
<tr>
<th>Institution</th>
<th>Postal address</th>
<th>City</th>
<th>State</th>
<th>Post Code</th>
<th>Nation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Western Health</td>
<td>Sunshine Hospital</td>
<td>Melbourne</td>
<td>VIC</td>
<td>3021</td>
<td></td>
</tr>
<tr>
<td>2 University of Melbourne</td>
<td>176 Furlong Road</td>
<td>Melbourne</td>
<td>VIC</td>
<td>3021</td>
<td></td>
</tr>
<tr>
<td>3 Box Hill Hospital</td>
<td>8 Arnold Street</td>
<td>Melbourne</td>
<td>VIC</td>
<td>3128</td>
<td></td>
</tr>
<tr>
<td>4 Alfred Hospital</td>
<td>Commercial Road</td>
<td>Melbourne</td>
<td>VIC</td>
<td>3181</td>
<td></td>
</tr>
<tr>
<td>5 Monash University</td>
<td>Central Clinical School</td>
<td>Melbourne</td>
<td>VIC</td>
<td>3004</td>
<td></td>
</tr>
</tbody>
</table>

Primary Keywords [Office use only] | Anatomy and physiology; Endocrine system diseases; Pharmaceutical preparations

Secondary keywords [Office use only] | Endocrinology; Diabetes mellitus, type 2; Pharmaceuticals

Notes:

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/MJA2.50898

This article is protected by copyright. All rights reserved
### Article details (press ctrl – 9 to enter details):

<table>
<thead>
<tr>
<th>Article type</th>
<th>Letter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blurb</td>
<td></td>
</tr>
</tbody>
</table>

### Office use

<table>
<thead>
<tr>
<th>Ms. Number</th>
<th>mja20.01297</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical editor</td>
<td>Francis Geronimo</td>
</tr>
<tr>
<td>Medical editor email</td>
<td><a href="mailto:fgeronimo@mja.com.au">fgeronimo@mja.com.au</a></td>
</tr>
<tr>
<td>Structural editor</td>
<td>Graeme Prince</td>
</tr>
<tr>
<td>Structural editor email</td>
<td><a href="mailto:gprince@mja.com.au">gprince@mja.com.au</a></td>
</tr>
<tr>
<td>Section/Category</td>
<td>Letters to the editor (reply)</td>
</tr>
<tr>
<td>Strapheading</td>
<td>Letter</td>
</tr>
</tbody>
</table>

### Wiley – file data:

- Filename for copyediting: ham_mja20.01297_ms
- Accompanying graphics
- Stock images
- Appendices

### Office use – history:

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original submission received</td>
<td>19/07/2020</td>
</tr>
<tr>
<td>Accept</td>
<td>20/08/2020</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Published (date format xx/xx/xx)</td>
<td>18/01/21</td>
</tr>
<tr>
<td>Issue</td>
<td>1</td>
</tr>
<tr>
<td>Vol</td>
<td>214</td>
</tr>
<tr>
<td>DOI</td>
<td>10.5694/mja20.01297</td>
</tr>
<tr>
<td>Journal</td>
<td>The Medical Journal of Australia</td>
</tr>
<tr>
<td>Original article DOI (for response)</td>
<td></td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved
Sodium–glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis

IN REPLY: We thank Meyer and colleagues for their interest in our article. The risk of sodium–glucose cotransporter type 2 (SGLT2) inhibitor-associated diabetic ketoacidosis in acutely unwell patients and people using ketogenic diets is already outlined in our article and does not require further comment.¹

We agree that the missed diagnosis of type 1 diabetes is an area of concern, but not just for patients taking SGLT2 inhibitors. In our 2019 study, 22% of patients with diabetic ketoacidosis who were thought to have type 2 diabetes were found to have type 1 diabetes, both in SGLT2 inhibitor users and non-users.² This health system factor clearly involves more than just the SGLT2 inhibitor-treated population.

While it is true that diabetic ketoacidosis has been more frequently reported with major surgery, including where ileus may contribute, clinicians need to be aware that it may also occur with other surgery, such as infected finger washout.² We agree that the advice regarding a glycated haemoglobin cut-off level of 75 mmol/mol (9%) for risk stratification is arbitrary; however, it is the value currently recommended by the Australian Diabetes Society.³ This is a rapidly evolving area and a more nuanced approach will no doubt be developed over time.

It is unclear whether the anecdotal case described in Meyer et al’s letter had ceased SGLT2 inhibitors for two full days before colonoscopy or only on the day of the procedure. We advise deferring non-urgent procedures in patients who have not withheld SGLT2 inhibitors for two full days before a procedure.

As stated in our article, ketonaemia levels that should raise concern in asymptomatic patients undergoing minor procedures are poorly defined. Indeed, we are currently conducting a multisite study to establish normal reference intervals for serum ketone concentrations in patients with and without diabetes undergoing colonoscopy. Universal measurement of serum ketone concentrations in all patients with type 2 diabetes must await further evidence from such studies regarding the expected normal range of serum ketone concentrations in the context of prolonged fasting and potential dehydration associated with colonoscopy.

Author details
Peter S Hamblin¹,²
Rosemary Wong³
Leon A Bach⁴

This article is protected by copyright. All rights reserved
1 Western Health, Melbourne, VIC.
2 University of Melbourne, Melbourne, VIC.
3 Box Hill Hospital, Melbourne, VIC.
4 Alfred Hospital, Melbourne, VIC.
5 Monash University, Melbourne, VIC.
peter.hamblin@wh.org.au

Competing interests: No relevant disclosures.

doi: 10.5694/mja20.01297

References


Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Hamblin, PS; Wong, R; Bach, LA

Title:
Sodium-glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis

Date:
2020-12-21

Citation:

Persistent Link:
http://hdl.handle.net/11343/276767